Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)

The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

invasive breast cancer
adjuvant therapy
cancer
breast cancer
  • 28 views
  • 03 Mar, 2022
  • 4 locations
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in regimens with and without atezolizumab. Following the neoadjuvant part of the study, after surgery all patients will continue to receive trastuzumab and …

tubal ligation
residual tumor
cyclophosphamide
carboplatin
pertuzumab
  • 105 views
  • 15 Feb, 2022
  • 11 locations
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients

  • 0 views
  • 19 Nov, 2021
  • 28 locations
Remote Ischemic Conditioning in Oncology

This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study is to determine if performing remote ischemic …

  • 0 views
  • 26 Jun, 2021
  • 1 location
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed dose-escalation schema every 21 days to establish the maximum tolerated dose (MTD) of the combination …

  • 0 views
  • 12 May, 2022
  • 1 location
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs (RESILIENCE)

(RIPC) in Non-Hodgkin lymphoma (NHL) patients receiving anthracyclines.

  • 0 views
  • 15 Mar, 2022
  • 2 locations
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in

invasive breast cancer
cyclophosphamide
triple negative breast cancer
anthracyclines
core needle biopsy
  • 126 views
  • 23 Jan, 2021
  • 12 locations
Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy

failure) are related to the use of anthracyclines. Anthracyclines are part of the chemotherapy regimen for solid tumors and hematological neoplasms in children and adults, and are associated with an

treatment regimen
anthracyclines
primary cancer
  • 0 views
  • 08 Oct, 2021
  • 1 location
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

with very limited mature B-NHL (R1 and R2 stage I and II) of substituting anthracyclines by the rituximab window without compromising survival rates. the effectiveness (event-free survival

  • 538 views
  • 16 Jun, 2021
  • 93 locations
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064)

ATO/ATRA protocol with the addition of two doses of IDA (50% compared to standard AIDA induction) for induction because of the anticipated need of adding anthracyclines to control hyperleukocytosis

cytarabine
mitoxantrone
secondary mds
methotrexate
consolidation therapy
  • 0 views
  • 07 Apr, 2022
  • 7 locations